Skip to main content
. 2009 Sep 15;23(18):2152–2165. doi: 10.1101/gad.1820109

Figure 4.

Figure 4.

Anti-angiogenic therapy quasinormalizes the angiogenic miR signature, and evokes elements of the metastatic miR signature. (A) miRs up-regulated in angiogenic islets and down-regulated by sunitinib treatment. (B) miRs up-regulated in angiogenic islets, down-regulated by sunitinib treatment, and similarly down-regulated in metastatic lesions. (N) Normal; (H) hyperplastic; (A) angiogenic; (T) tumor; (C) control-treated tumors; (S) sunitinib-treated tumors; (ML) met-like primary tumors; (M) metastases. (C) FACS of the constituent cell types of tumors followed by Q-PCR analysis reveals that affected miRs reflect either the differential abundance of the tumor vasculature and its component endothelial cells and pericytes, or altered regulation of miRs in the predominant population of cancer cells. (Open bars) (NT) Not treated. (Colored bar) (Su) Sunitinib treated; (ps) presort; (EC) endothelial cells; (IC) immune cells; (PC) pericytes; (OC) other cells.